RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DELL'AQUILA E
Collezione AOU Città della Salute di Torino

Items : 5

Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO. in Clinical colorectal cancer / Clin Colorectal Cancer. 2022 Sep;21(3):220-228. doi: 10.1016/j.clcc.2022.02.003. Epub 2022 Feb 19.

2022
AOU Città della Salute di Torino

Cupini S; Fanchini L; Zaniboni A; Buonadonna A; Tomasello G; Provenzano L; Spagnoletti A; Daniel F; Bergamo F; Germani MM; Conca V; Boccaccino A; Stellato M; Galletti A; Rossini D; Dell'Aquila E; Carlomagno C; Caponnetto S; Rapisardi S; Santini D;

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15.

2022
ASL Torino 4
AOU Città della Salute di Torino

Ferri C; Parisi A; Ficorella C; Cortellini A; Pensieri MV; Aimar G; Roberto M; Petrillo A; Zoratto F; Spinelli GP; Garajova I; Vitale P; Zanaletti N; De Tursi M; Di Pietro FR; Morelli C; Giampieri R; Depetris I; Keränen SR; Lombardi P; Zurlo IV; Dell'Aquila E; Gelsomino F; Ghidini M; Nigro O; Filippi R; Salvatore L; Porzio G; Fargnoli MC; et alii...

Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis. in Frontiers in oncology / Front Oncol. 2022 Aug 12;12:935826. doi: 10.3389/fonc.2022.935826. eCollection 2022.

2022
ASL Torino 4
AOU Città della Salute di Torino

Berardi R; Galassi B; Ferri C; Garrone O; Zoratto F; Ciardiello D; Pensieri MV; Tomao S; Depetris I; Di Pietro FR; Dell'Aquila E; Giordano G; Landriscina M; Vitale P; Zurlo IV; De Tursi M; Di Marino P; Daniele B; Satolli MA; Petrillo A; Strippoli A; Filippi R; Bensi M; Maratta MG; Salvatore L; Ghidini M; Felicetti C; Giampieri R; Mammarella A; et alii...

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. in Clinical colorectal cancer / Clin Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. Epub 2021 Jul 18.

2021
ASL Torino 4
AOU Città della Salute di Torino

D'Orazio C; Ficorella C; Petrillo A; Ierino D; Spinelli GP; Roberto M; Zoratto F; Ghidini M; Vitale P; Garajova I; Troiani T; Di Pietro FR; De Galitiis F; Zanaletti N; Tinari N; Morelli C; Giampieri R; De Tursi M; Aimar G; Depetris I; Lombardi P; Keränen SR; Claudia F; Leo S; Dell'Aquila E; Spallanzani A; Zurlo V; Gelsomino F; Nigro O; et alii...

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004.

2018
AOU Città della Salute di Torino

Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D;